Current filters:

Bristol-Myers SquibbAmgen

1 to 9 of 109 results

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA


US drug major Bristol-Myers Squibb (NYSE: BMY) announced on Friday that the European Commission has granted…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEnbrelEuropeHumiraMarkets & MarketingNorth AmericaOrenciaPfizerPharmaceuticalRegulation

Highlights of presentations planned for ASCO meeting


Ahead of the annual American Society of Clinical Oncology (ASCO) meeting which takes place in Chicago…

AmgenBayerBiotechnologyBristol-Myers SquibbOncologyPharmaceuticalResearchSanofi

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis


In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

Executive appointments at Bristol-Myers Squibb and Amgen


US drug major Bristol-Myers Squibb (NYSE: BMY) has announced a series of related changes within its senior…

AmgenBiotechnologyBristol-Myers SquibbManagementPharmaceutical

Future pharmaceutical leaders in personalized medicine headed by Roche and Novartis


A new report from Diaceutics ( for the first time analyzes which pharmaceutical companies…

AmgenAstraZenecaBristol-Myers SquibbEli LillyGlaxoSmithKlineMarkets & MarketingMerck & CoNovartisPfizerPharmaceuticalResearchRocheSanofi-Aventis

1 to 9 of 109 results

Back to top